Table 1.
Demographic and Transplant Characteristics of the Allo-HCT Patients with or without Virus-Associated HC
| Characteristic | Patients with Virus-Associated HC (n = 759) | Patients without Virus-Associated HC (n = 12,604) | P Value | |
|---|---|---|---|---|
| Age | Mean ± SD | 39.4 ± 20.1 | 46.9 ± 20.7 | <.0001 |
| Sex, n (%) | Female | 281 (37.0) | 5443 (43.2) | .0008 |
| Male | 478 (63.0) | 7155 (56.8) | ||
| Health insurance plan type at time of allo-HCT procedure,* n (%) | Commercial | 661 (87.1) | 10,826 (85.9) | .3574 |
| Medicaid | 68 (9.0) | 745 (5.9) | .0006 | |
| Managed Medicaid | 31 (4.1) | 413 (3.3) | .2280 | |
| Medicare | 64 (8.4) | 1877 (14.9) | <.0001 | |
| Managed Medicare | 8 (1.1) | 249 (2.0) | .0726 | |
| VA/other | 64 (8.4) | 1228 (9.7) | .2353 | |
| Unknown | 39 (5.1) | 592 (4.7) | .5777 | |
| Region of the United States, n (%) | Northeast | 164 (21.6) | 3061 (24.3) | .0039 |
| Midwest | 166 (21.9) | 2769 (22.0) | ||
| South | 291 (38.3) | 4029 (32.0) | ||
| West | 90 (11.9) | 1799 (14.3) | ||
| Unknown | 48 (6.3) | 946 (7.5) | ||
| Underlying disease, n (%) | Malignant | 685 (90.3) | 11,157 (88.5) | .0004 |
| Nonmalignant immunodeficient | 7 (0.9) | 167 (1.3) | ||
| Nonmalignant immunocompetent | 61 (8.0) | 941 (7.5) | ||
| Inherited metabolic disorders | † | 31 (0.3) | ||
| Unknown | † | 308 (2.4) | ||
| Stem cell source, n (%) | Bone marrow | 94 (12.4) | 1703 (13.5) | .0002 |
| Peripheral blood | 542 (71.4) | 8862 (70.3) | ||
| Cord blood | 68 (9.0) | 727 (5.8) | ||
| Unknown | 55 (7.3) | 1312 (10.4) | ||
| Number of baseline comorbidities, mean ± SD | 2.1 ± 1.5 | 2.0 ± 1.6 | .2479 | |
VA indicates Veterans Administration.
*
Nonexclusive categories.
†
Cells with ≤5 observations are not reported.